Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 19/20 | 0.66 |
| ▸ | DRD2 | P14416 | 18/20 | 0.66 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881765 | 0.89 | DRD3 (0.56) | DRD3KCNH2DRD2 | |
| SCHEMBL4867467 | 0.89 | DRD3 (0.51) | DRD3KCNH2DRD2 | |
| SCHEMBL4876086 | 0.88 | DRD3 (0.52) | DRD3KCNH2DRD2 | |
| SCHEMBL4880119 | 0.88 | DRD3 (0.54) | DRD3KCNH2DRD2 | |
| SCHEMBL4875836 | 0.88 | DRD3 (0.51) | DRD3KCNH2DRD2 | |
| SCHEMBL4880857 | 0.87 | DRD3 (0.51) | DRD3KCNH2DRD2 | |
| SCHEMBL4879702 | 0.86 | DRD3 (0.53) | DRD3KCNH2DRD2 | |
| Formic Acid SCHEMBL4877759 | 0.85 | DRD3 (0.85) | DRD3KCNH2DRD2 | |
| SCHEMBL14162809 | 0.84 | DRD3 (0.90) | DRD3KCNH2DRD2 | |
| SCHEMBL4880728 | 0.75 | DRD3 (0.39) | DRD3KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | claimed |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| EP-1737851-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | GLAXO GROUP LIMITED (GB) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005087764-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | DRD3, DRD2, SLC6A3 | DRD3 1/4885KCNH2 399/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.